Anupam Rasayan India releases annual report, highlights strategic growth and sustainability

Anupam Rasayan India Limited submitted its Integrated Annual Report for the financial year 2024-25, along with the Notice of the 22nd Annual General Meeting. The report details significant progress and strategic initiatives. The company commercialized 9 new molecules in FY2024-25, expanding its product portfolio to 79, and increased the pharmaceutical segment’s revenue share from 9% in FY2023-24 to 22% in FY2024-25. Total revenue from operations stood at ₹8,958.99 million (standalone) and ₹14,369.74 million (consolidated) for FY2024-25.

Key sustainability achievements include a 9.2% reduction in Scope 1 GHG emissions from FY2023-24, a 42.58% reduction in Scope 2 Net Zero emissions by 2027, and an 87.15% waste diversion from landfills. The company has invested ₹593 million in a 9.6 MW hybrid solar-wind plant, contributing to over 65% of electricity requirements from renewable sources.

The report also includes the appointment of M/s. Natvarlal Vepari & Co., Chartered Accountants, Surat, as the new statutory auditor for a term of five years, replacing M/s. Rajendra & Co. Additionally, Anand Sureshbhai Desai and Mona Anandbhai Desai are proposed for re-appointment as managing director and whole-time director, respectively, for five-year terms commencing April 1, 2026.